Background
-
Group A: tumors with a high mutational load (> 100 somatic single-nucleotide variants/exome)In addition to a small fraction of pediatric tumors with a true hypermutated phenotype in the context of constitutional mismatch repair deficiency, sporadic tumors can also carry a high mutational load. In a meta-analysis of trials across various adult cancer types treated with anti-PD1/PDL1-Ab as single agent, a low tumor mutational burden of ≤5/megabase (MB) (approximately corresponding to < 100 single-nucleotide variant (SNV)/exome) was associated with 12% response rate versus medium/high mutational burden of 6/MB or greater (corresponding to > 100 SNV/exome) associated with 43% response rate [27]. Within the INFORM registry molecular diagnostic pipeline ~ 6% of patients across a variety of entities show a mutational burden of > 100 somatic missense SNVs/exome. Thus, group A includes sporadic patients with a high mutational load (> 100 somatic missense SNVs/exome) in addition to patients with true hypermutation.
-
Group B: high PD-L1 mRNA expressing tumorsIncreased PD-L1 expression is associated with clinical responses to nivolumab in adult non–small-cell lung cancer [28]. Within the INFORM registry molecular diagnostic pipeline ~ 7% of patients across a variety of entities show an increased PD-L1 mRNA expression (CD274: defined as reads per million total reads per kilobase of exon model (RPKM) by RNA-Seq > 3), independent from the high mutational load phenotype.
-
Group C: tumors with high-level MYC or MYCN (MYC(N)) amplificationVery compelling recent preclinical data strongly suggests that HDACi are active against MYC(N) amplified tumors [29‐32]. In addition, MYC is reported to upregulate PD-L1 [33]. Within the INFORM registry molecular diagnostic pipeline ~ 5% of patients across a variety of entities show MYC(N) amplification. The broad immunological effects of entinostat which can synergize with checkpoint inhibition will therefore be exploited in this group of very aggressive tumors in addition to a direct inhibiting effect on MYC(N) function and expression.
-
Group D: tumors with a low mutational load, low PD-L1 mRNA expression and no MYC(N) amplificationThis “biomarker low” group allows exploring activity in patients with tumors harboring a low mutational burden/PD-L1 expression/no MYC(N) amplification. Because of the above described immune enhancing activity of entinostat, it is postulated that these patients may also benefit from the combination treatment.
Methods/design
Study design
-
In case the efficacy criterion is met, no early stopping is planned. However, early evidence of efficacy may set in motion the conception of a subsequent phase II/III trial.
-
In case neither the efficacy nor the futility criterion is met, recruitment will continue.
-
In case the futility criterion is met, recruitment of patients will be suspended and the DMC will be notified. The DMC will advise the coordinating investigator whether to terminate or to amend the trial.
Study objectives
Primary objective phase I
Primary objective phase II
Secondary objectives
-
Comparison of patient outcomes in group D (biomarker low) with all biomarker positive groups A, B and C (pooled and separately)
-
Comparison of patient outcomes in group A-D with matching groups of the INFORM registry (pooled and separately)
-
Evaluation of somatic SNV count as a predictive biomarker: relation of patient outcomes to the level of somatic SNVs
-
Evaluation of PD-L1 mRNA expression as a predictive biomarker: relation of patient outcomes to the level of PD-L1 mRNA expression
-
Evaluation of the level of MYC(N) amplification as a predictive biomarker: relation to patient outcomes
-
Evaluate activity using immune related response evaluation methods
-
Entinostat plasma PK (cerebrospinal fluid (CSF) if appropriate (e.g. if CSF has to be obtained for clinical reasons))
Exploratory objectives
-
Exploration of molecular resistance/relapse mechanisms
-
Exploration of relevant germline and somatic variants of pharmacogenes (absorption, distribution, metabolism and excretion (ADME)) and their association with treatment response, adverse events and drug metabolism
-
Exploration of response prediction of a co-clinical patient derived xenograft (PDX) model and drug testing program
-
Explore prediction of neoantigens in relation to SNV counts
-
Evaluate the correlation of the level of PD-L1 expression by immunohistochemistry with mRNA expression and patient outcomes
-
Evaluate phenotype and function of peripheral immune cells and response to treatment as a predictive biomarker
-
Exploration of tumor infiltrating immune cell populations by mRNA expression as a potential predictive biomarker for response
-
Exploration of gene signatures as potential predictive biomarkers for response
-
Exploration of activation of cryptic transcription start sites as a predictive biomarker
-
Exploration of the role of aneuploidy in response to the combination treatment
-
Exploration of the role of CD28/B7 costimulatory pathway in response to the combination treatment
-
Exploration of the possible role of circulating tumor DNA for monitoring of therapy response and resistance
Trial end points
Primary end points phase I (outcomes)
-
Grade ≥ 3 AE of any duration, please see exceptions below.
-
Any immune mediated adverse event, regardless of grade, which requires discontinuation of study treatment (e.g. pneumonitis, hypersensitivity reaction, acute kidney injury) will be a DLT.
-
A cumulative delay of ≥14 days of combination treatment for reasons of toxicity during the DLT observation period (first 5 weeks), please see exceptions below.
-
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin Grade ≥ 3 elevation of any duration.
-
Grade 4 laboratory values included in the visit schedule of any duration (not listed in the exceptions below).
-
Laboratory value AEs:
-
Leukopenia, anemia and neutropenia: resolved to Grade 2 within 14 days (unsupported).
-
Alkaline phosphatase asymptomatic Grade 3 elevation of any duration.
-
Electrolyte abnormalities of any Grade resolving to Grade 1 ≤ 7 days (independent of intervention).
-
Lipase or amylase asymptomatic increase of any Grade and duration.
-
Lymphocytopenia of any Grade and duration.
-
All other Grade ≤ 3 laboratory values resolved to Grade 0–1 within 14 days.
-
Other AEs:
-
Grade ≤ 3 neurologic AE consistent with immune-treatment effect (i.e., due to peri-tumoral edema/reaction in brain tumors) and resolved to Grade 0–1 within 14 days (with appropriate treatment).
-
Fever or vomiting lasting less than 3 days.
-
Fatigue: resolved to Grade 2 within 14 days.
Primary end point phase II (outcomes)
Secondary end points (outcomes)
-
Duration of Response (DOR).
-
Disease Control Rate (DCR).
-
Stable disease (SD).
-
Progression-free survival (PFS).
-
Time to Response (TTR).
-
Overall Survival (OS).
-
Immune related Response Rate (RR) measured by immune-related RECIST (iRECIST) criteria and immunotherapy RANO (iRANO) criteria by central review.
-
Entinostat plasma PK.
Exploratory end points (outcomes)
-
Assessment of circulating tumor DNA in peripheral blood at baseline and at every response evaluation.
-
Response prediction in a co-clinical PDX model and drug testing program.
-
Immune phenotyping (FACS panel) and Luminex cytokine panel in peripheral blood at baseline, after the priming week and after 5 weeks of initiation of therapy.
-
Analyze mRNA expression data for tumor infiltrating immune cell populations.
-
Analyze gene signatures in whole exome data.
-
Test induction of cryptic transcription start sites at baseline, after priming and after 5 weeks of initiation of therapy.
-
Determination of SNV load by different methods (WES, Panel-Seq).
Trial participants
Dosing and dose adjustments
-
Phase I: After the occurrence of a DLT in phase I in dose level 2, it is allowed to de-escalate to dose level 1 (see Additional file 2) intra-individually if this is conform the dose-adjustment rules (provided in Additional file 3). If phase I patients do not tolerate dose level 1, treatment should be discontinued.
-
Phase II: The dose de-escalation scheme is depicted in Additional file 2. For patients in dose level 1 it can be considered to de-escalate to nivolumab monotherapy (dose level − 1). If this is also not tolerated, treatment should be discontinued. Treatment modifications for toxicity are described in Additional file 3.
Assessments and collection of outcomes
Data collection
Primary outcome phase I
Primary outcome phase II
Sample size
Statistical methods
Primary outcome phase I
Primary outcome phase II
Secondary outcomes
Discussion
Trial status
-
Protocol version: 9 January 2019, Final2
-
Date recruitment start: 26 July 2019
-
Estimated recruitment completion: Q3 2021
-
Trial registration: ClinicalTrials.gov, NCT03838042. Registered on 12 February 2019.